Pharmacological subgroup
L01X – ANDERE ANTINEOPLASTISCHE MITTEL
61Decisions
87Patient groups
Added benefit by patient group
- Considerable16
- Minor9
- Non-quantifiable14
- Not proven47
- Lesser benefit1
Subgroups
- L01XG Proteasom-Inhibitoren 3 decisions
- L01XH Histon-Deacetylase (HDAC)-Inhibitoren 1 decision
- L01XJ Hedgehog-Signalweg-Inhibitoren 3 decisions
- L01XK Poly-ADP-Ribose-Polymerase (PARP)-Inhibitoren 17 decisions
- L01XL Antineoplastische Zell- und Gentherapie 17 decisions
- L01XM Isocitrat-Dehydrogenase (IDH)-Inhibitoren 3 decisions
- L01XX Andere antineoplastische Mittel 16 decisions
- L01XY Kombinationen von antineoplastischen Mitteln 1 decision
Decisions, newest first
- 2026-09-03AkeegaNiraparib/AbirateronacetatNot proven: 2 of 2 patient groups
- 2026-08-20TibsovoIvosidenibNot proven
- 2026-08-20TibsovoIvosidenibNot proven
- 2026-06-04BreyanziLisocabtagen maraleucelNot proven
- 2026-05-07VoranigoVorasidenibNon-quantifiable
- 2026-04-02OgsiveoNirogacestatMinor
- 2025-10-02BreyanziLisocabtagen maraleucelNot proven
- 2025-09-18WeliregBelzutifanNot proven
- 2025-09-18WeliregBelzutifanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-05-15CarvyktiCiltacabtagen autoleucelConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-02-20LynparzaOlaparibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-12-19YescartaAxicabtagen-CiloleucelMinor
- 2024-09-19AbecmaIdecabtagen vicleucelNot proven
- 2024-08-15TalzennaTalazoparibNot proven: 2 of 3 patient groupsLesser benefit: 1 of 3 patient groups
- 2024-06-06RubracaRucaparibNot proven
- 2024-05-16KimmtrakTebentafuspConsiderable
- 2024-05-02AkeegaNiraparib/AbirateronacetatConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-02-15KymriahTisagenlecleucelNon-quantifiable
- 2024-02-15KymriahTisagenlecleucelNon-quantifiable
- 2023-12-21YescartaAxicabtagen-CiloleucelNot proven
- 2023-11-16BreyanziLisocabtagen maraleucelConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-10-05EbvalloTabelecleucelNon-quantifiable
- 2023-09-21RubracaRucaparibNot proven
- 2023-09-21LynparzaOlaparibNot proven
- 2023-08-03LumykrasSotorasibNon-quantifiable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-07-06LynparzaOlaparibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-04-20LynparzaOlaparibConsiderable
- 2023-04-06BreyanziLisocabtagen maraleucelNot proven
- 2023-03-16TecartusBrexucabtagen autoleucelNon-quantifiable
- 2023-03-16NexpovioSelinexorNot proven
- 2023-03-16NexpovioSelinexorNot proven
- 2023-02-16LynparzaOlaparibMinor
- 2022-12-01KymriahTisagenlecleucelNon-quantifiable
- 2022-11-03YescartaAxicabtagen-CiloleucelNon-quantifiable: 2 of 2 patient groups
- 2022-08-04LumykrasSotorasibNot proven
- 2022-06-16AbecmaIdecabtagen vicleucelNon-quantifiable
- 2022-04-21NinlaroIxazomibNon-quantifiable
- 2021-12-02VenclyxtoVenetoclaxConsiderable
- 2021-12-02ElzonrisTagraxofuspNon-quantifiable
- 2021-08-05TecartusBrexucabtagen autoleucelNon-quantifiable
- 2021-07-15ZejulaNiraparibNot proven
- 2021-07-15KyprolisCarfilzomibNot proven
- 2021-06-03LynparzaOlaparibConsiderable
- 2021-06-03LynparzaOlaparibNot proven
- 2021-05-20ZejulaNiraparibNot proven
- 2021-02-18DaurismoGlasdegibConsiderable
- 2020-11-20TalzennaTalazoparibConsiderable
- 2020-10-15VenclyxtoVenetoclaxNot proven: 3 of 3 patient groups
- 2020-01-16LynparzaOlaparibMinor
- 2019-05-16VenclyxtoVenetoclaxNot proven: 2 of 2 patient groups
- 2019-05-16VenclyxtoVenetoclaxMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-03-22Vyxeos liposomalDaunorubicin/CytarabinConsiderable
- 2018-12-06LynparzaOlaparibMinor
- 2018-08-02OdomzoSonidegibNot proven
- 2018-02-15KyprolisCarfilzomibConsiderable: 2 of 2 patient groups
- 2016-12-15ImlygicTalimogen laherparepvecNot proven: 3 of 3 patient groups
- 2016-12-01HalavenEribulinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-08-04ErivedgeVismodegibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-03-17FarydakPanobinostatNon-quantifiable
- 2015-01-22HalavenEribulinConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2013-08-15ZaltrapAfliberceptMinor
Data status: 2026-10-29